• About Us
  • Contact
  • Blog
  • Visit Us

teva stock price nyse

Thomas Morstead Wife, Doom Patrol Episode 11 Recap, Rachel Hollis Parents, Chaos Legion Characters, Mastercard Online Application, Uga Economic Outlook 2020, Secret Photo App, Strawberry Peak Alltrails, Resin Art Molds, Philip Carey Height, Bubble Tea Game,

Find the latest Teva Pharmaceutical Industries (TEVA) stock quote, history, news and other vital information to help you with your stock trading and investing. Teva Pharmaceutical Industries issued an update on its FY20 earnings guidance on Thursday, May, 7th. Teva Pharmaceutical Industries had a negative net margin of 4.73% and a positive return on equity of 18.10%. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. Under Special Management (0.31%), Strs Ohio (0.07%), Raymond James & Associates (0.05%) and Raymond James Financial Services Advisors Inc. (0.04%). Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Interested parties can register for or listen to the call using Teva Pharmaceutical Industries Ltd (NYSE:TEVA) released its quarterly earnings results on Thursday, May, 7th. 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. Their forecasts range from $8.00 to $16.00. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Stock analysis for Teva Pharmaceutical Industries Ltd (TEVA:New York) including stock price, stock chart, company news, key statistics, fundamentals and company profile. See what's happening in the market right now with MarketBeat's real-time news feed.

Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Learn everything you need to know about successful options trading with this three-part video course.Looking for new stock ideas? Combining the high performance of NYSE Pillar technology with a taker/maker fee schedule.

Shares of TEVA can be purchased through any online brokerage account. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.Get daily stock ideas top-performing Wall Street analysts. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. © 2020 Market data provided is at least 10-minutes delayed and hosted by Offering traders deep liquidity across listed option contracts. There are currently 4 sell ratings, 12 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." Teva stock price target raised to $16 from $11 at SunTrust RH Jun. The company reported $0.76 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.59 by $0.17. On average, they anticipate Teva Pharmaceutical Industries' stock price to reach $11.67 in the next twelve months. Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Sol J Barer and Sven Dethlefs. Teva Pharmaceutical Industries Limited (TEVA) Add to watchlist. High institutional ownership can be a signal of strong market trust in this company.Earnings for Teva Pharmaceutical Industries are expected to grow by 5.42% in the coming year, from $2.40 to $2.53 per share.The P/E ratio of Teva Pharmaceutical Industries is -16.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.The P/E ratio of Teva Pharmaceutical Industries is -16.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Teva Pharmaceutical Industries has a PEG Ratio of 0.82. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.Teva Pharmaceutical Industries' management team includes the following people: During the same quarter last year, the firm earned $0.60 earnings per share. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. Since then, TEVA shares have increased by 35.6% and is now trading at $12.22. The company provided earnings per share (EPS) guidance of $2.30-2.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.44. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries employs 40,039 workers across the globe.The official website for Teva Pharmaceutical Industries is Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131.

View our full suite of financial calendars and market data tables, all for free.Receive a free world-class investing education from MarketBeat.

© American Consumer News, LLC dba MarketBeat® 2010-2020. Top institutional investors include Harel Insurance Investments & Financial Services Ltd. (0.70%), Sumitomo Mitsui Trust Holdings Inc. (0.38%), Mivtachim The Workers Social Insurance Fund Ltd. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. The company can be reached via phone at 972-3914-8171 or via email at Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. "Teva Pharmaceutical Industries' stock is owned by a number of institutional and retail investors. Want to see which stocks are moving? Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease.

teva stock price nyse 2020